volume 4, issue 3, P136-138 2021
DOI: 10.1002/iju5.12261
View full text
|
|
Share
Shotaro Yasuoka, Takeshi Yuasa, Motohiro Fujiwara, Junko Fujisaki, Kentaro Inamura, Yoshinobu Komai, Noboru Numao, Shinya Yamamoto, Junji Yonese

Abstract: Introduction Metastatic renal cell carcinoma is treated with various regimens. As their outcomes are improving and follow‐up periods are growing longer, the rate of unusual visceral metastases may increase. Case presentation A 68‐year‐old man diagnosed with lung, pancreatic, and renal metastases 9 years after left partial nephrectomy and a diagnosis of pT1a clear cell renal cell carcinoma started molecular targeted therapy using sunitinib. Nine years after the initiation of targeted therapy, a mass lesion in t…

expand abstract